Eli Lilly and Company’s (LLY) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Eli Lilly and Company (NYSE:LLY) in a report published on Tuesday, Benzinga reports. Cantor Fitzgerald currently has a $885.00 price target on the stock, up from their previous price target of $815.00.

Several other research firms also recently weighed in on LLY. The Goldman Sachs Group upped their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a neutral rating in a research note on Thursday, April 11th. Bank of America lifted their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a buy rating in a research report on Friday, March 1st. Wells Fargo & Company increased their price objective on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an overweight rating in a research report on Tuesday, February 6th. Barclays lifted their target price on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an overweight rating in a report on Wednesday, February 7th. Finally, Erste Group Bank upgraded shares of Eli Lilly and Company from a hold rating to a buy rating in a report on Wednesday, April 3rd. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of Moderate Buy and a consensus price target of $757.95.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $734.97 on Tuesday. Eli Lilly and Company has a 1 year low of $419.80 and a 1 year high of $800.78. The stock has a market capitalization of $698.52 billion, a P/E ratio of 108.24, a P/E/G ratio of 1.57 and a beta of 0.37. The company’s 50-day moving average is $761.75 and its 200 day moving average is $670.56. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 0.73.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. During the same period in the previous year, the firm posted $1.62 EPS. The business’s revenue was up 26.0% on a year-over-year basis. On average, sell-side analysts expect that Eli Lilly and Company will post 13.49 earnings per share for the current year.

Institutional Investors Weigh In On Eli Lilly and Company

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Versant Capital Management Inc grew its stake in shares of Eli Lilly and Company by 1.8% during the 1st quarter. Versant Capital Management Inc now owns 736 shares of the company’s stock valued at $573,000 after acquiring an additional 13 shares during the period. Twin Peaks Wealth Advisors LLC lifted its holdings in Eli Lilly and Company by 2.0% during the first quarter. Twin Peaks Wealth Advisors LLC now owns 718 shares of the company’s stock valued at $559,000 after purchasing an additional 14 shares in the last quarter. Pitti Group Wealth Management LLC boosted its position in shares of Eli Lilly and Company by 0.8% in the first quarter. Pitti Group Wealth Management LLC now owns 1,673 shares of the company’s stock worth $1,271,000 after purchasing an additional 14 shares during the period. Ulland Investment Advisors LLC increased its stake in shares of Eli Lilly and Company by 7.0% in the first quarter. Ulland Investment Advisors LLC now owns 214 shares of the company’s stock worth $166,000 after purchasing an additional 14 shares in the last quarter. Finally, Moseley Investment Management Inc. raised its position in shares of Eli Lilly and Company by 0.4% during the 1st quarter. Moseley Investment Management Inc. now owns 3,890 shares of the company’s stock valued at $3,027,000 after purchasing an additional 14 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.